Vir Biotechnology, Inc. Deferred Foreign Income Tax Expense (Benefit)
Vir Biotechnology, Inc. (VIR) reported Deferred Foreign Income Tax Expense (Benefit) of $2.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2026-02-23
- Vir Biotechnology, Inc. deferred foreign income tax expense (benefit) for fiscal 2025 was $2.00K, a 96.43% decline from fiscal 2024.
- Vir Biotechnology, Inc. deferred foreign income tax expense (benefit) for fiscal 2024 was $56.00K.
- Vir Biotechnology, Inc. deferred foreign income tax expense (benefit) for fiscal 2023 was -$59.00K.
- Vir Biotechnology, Inc. deferred foreign income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $2.00K 10-K · filed 2026-02-23 |
| 2024-12-31 | $56.00K 10-K · filed 2026-02-23 |
| 2023-12-31 | -$59.00K 10-K · filed 2026-02-23 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $0.00 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |